Sort by
Refine Your Search
-
neuromuscular disease, as well as gain exposure to Scholar Rock’s broader neuromuscular pipeline of innovative therapies. Through core areas such as medical communications, publications, medical information, and
-
orthosteric) and ion channels (a4b2 nAChR, a7nAChR, a9* nAChR, GIRK1/2, GIRK1/4etc.). Key initial responsibilities will include biochemical and ADME/PK studies and data analysis, SAR hypothesis generation
-
skills in the analysis, interpretation, and communication of clinical data, and expand their scientific knowledge to render clinical insights and contribute to meeting customer needs. Responsibilities Gain
-
gather insights from stakeholders, identify data and knowledge gaps, and respond to medical inquiries in a clear and scientifically accurate manner to guide healthcare provider and payer decision making
-
. For more information, visit www.takeda.com . Responsibilities Takeda Pharmaceutical Company is committed to striving towards better health for people and a brighter future for the world through
-
scientific and strategic assistance to safety product leads to support Alnylam products · Participate in the collection, interpretation, and presentation of safety data in internal forums · Support
-
. Through hands-on experience, fellows will work with various cross-functional teams to learn the role of Medical Affairs, develop skills in the analysis, interpretation, and communication of clinical data
-
internal partners and delivers on the medical plan. US Medical directors play a key role in informing global product development and data generation strategies with perspective of US Region. The team also
-
of their choice, with options including Scientific Communications, Medical Information, Field Medical, or Medical Operations for the second year. Medical Affairs Fellowship Objectives: Develop in-depth knowledge
-
Communications, Medical Information, Field Medical, or Medical Operations for the second year. Medical Affairs Fellowship Objectives: · Develop in-depth knowledge of Intellia’s CRISPR gene editing technology